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Keloid scarring is a fibroproliferative disorder due to the accumulation of collagen type I. Tolfenamic acid (TA), a nonsteroidal
anti-inflammatory drug, has been found to potentially affect the synthesis of collagen in rats. In this preliminary study, we aimed
to test the effects of TA on cell proliferation, cell apoptosis, and the deposition of intracellular collagen in keloid fibroblasts.
Normal fibroblasts (NFs) and keloid fibroblasts (KFs) were obtained from human dermis tissue. Within the dose range 10−3–
10−6M and exposure times 24 h, 48 h, and 72 h, we found that 0.55 × 10−3M TA at 48 h exposure exhibited significantly decreased
cell proliferation in both NFs and KFs. Under these experimental conditions, we demonstrated that (1) TA treatment induced
a remarkable apoptotic rate in KFs compared to NFs; (2) TA treatment reduced collagen production in KFs versus NFs; (3) TA
treatment decreased collagen type I expression in KFs comparing to that of NFs. In summary, our data suggest that TA decreases
cell proliferation, induces cell apoptosis, and inhibits collagen accumulation in KFs.
1. Introduction
Keloid scarring, is a raised scar which forms by expanding
beyond the boundaries of the original lesion [1]. The main
histological manifestation of a keloid scar is the overgrowth
of atypical fibroblasts with excessive accumulation of extra-
cellular matrix components, especially collagen, fibronectin,
elastin, and proteoglycans [1–4]. The causes of this type of
scar are still unknown, but it has been pointed out that
keloid scars can develop after any dermal abrasion including
burns, piercing, or surgery [1–6]. Differing from normal
wound healing, keloid scar formation begins with abnormal
tissue growth in the dermal lesion extending beyond the
borders of the original wound [7–11].The central pathological
wound healing response of keloid scarring is composed of a
high density of mesenchymal cells called keloid fibroblasts
(KFs) [9, 10]. Consequently, the over growth of KFs results
in overabundance of extracellular and intracellular matrix
stroma, which is classified by irregularly directed and thick
hyalinized spiral bundles described as keloidal collagen [5,
12]. During the formation of keloid scars, the type of collagen
initially secreted by fibroblasts is granular collagen type III.
Throughout the maturation of the process, collagen type I
gradually replaces collagen type III and eventually comprises
extracellular matrix in 99% of the wound bed [1, 5, 9–12].
Current, common treatments for keloids are often a combi-
nation of excision followed by a reconstructive surgical pro-
cedure. Glucocorticoids or 5-fluorouracil injections followed
by compression therapy such as silicone sheets are frequently
employed [1, 2]. Nonetheless, recurrence remains between
45% and 100% [3, 4]. Therefore, treatment of keloids contin-
ues to be a great challenge for the reconstructive surgeon.
Tolfenamic acid (TA) is a fenamic acid derivative belong-
ing to the nonsteroidal anti-inflammatory drug (NSAID)
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Figure 1: Structure of tolfenamic acid.
class that is traditionally used for rheumatic diseases
[13, 14]. The predominant medical uses of this group
of drugs include rheumatoid arthritis, osteoarthritis, and
inflammatory arthropathies [15–18]. TA, also written as 2-
([3-chloro-2-methylphenyl]-amino)-benzoic acid in IUPAC
terms (Figure 1), has a low solubility in water and molecular
weight of 261.7 g/mol.The exactmedical applications, adverse
effects, and mechanism of TA are not clear. However, pre-
vious studies have described highly specific applications of
TA. Studies illustrate that TA is associated with inhibiting
collagen metabolism in connective tissue in rats and has the
capacity to induce cancer cell apoptosis [13, 14, 19–25]. There
is an inhibition of sodium tolfenamate on the metabolism
of collagen with 0.15mol/L NaCl in rats [13]. TA reduces
cell survival, growth, and angiogenesis in tumor and cancer
cells, including human xenograft tumor, human pancreatic
cancer, human neuroblastoma, and mouse prostate cancer
by regulating the activity of transcription factor Sp1; human
head and neck cancer by regulating NADAG-1; human
colorectal cancer via ESE-1/EGR-1; and human oral cancer by
affecting the p38 mitogen-activated protein kinase signaling
pathway [14, 19–23].
2. Materials and Methods
2.1. Cell Culture and Chemicals. All skin samples were
obtained underWright State University IRB number SC4833.
A sample of scar tissue (KF1) was taken from a 24-year-
old African-American male with clinical and pathologic
evidence of keloid scarring confirmed as previously described
[10, 26]. A second keloid fibroblast cell line (KF2) was
obtained from a 35-year-old African-American female was
purchased fromATCC (Passage 11, ATCC,USA).Onenormal
adult skin sample (NF) was obtained from a 29-year-old
African-American female during plastic surgery [7, 8]. Skin
specimens were incubated with 2mL digestion medium
containing high glucose Dulbecco’sModified Eagle’sMedium
(DMEM) (Gibco, Life Technologies, USA), 5mg/mL collage-
nase/dispase II (RocheDiagnostics, USA), and 0.25% trypsin
(Invitrogen, Life Technologies, USA) for 8 hours under 5%
CO
2
, at 37∘C [7, 9, 27]. Isolated fibroblasts passages (P)
0 from keloid scar tissue and normal dermis tissue were
cultured in totalmedium comprising of high glucoseDMEM,
10% fetal bovine serum (Gibco, Life Technologies, USA), 1%
pen/strep/glutamine (Invitrogen, Life Technologies, USA) in
the condition of 5% CO
2
, at 37∘C. Each cell line was cultured
separately. KF1 P13 to P15, KF2 P 3 to 5, and NF P3–P8 were
tested in all assays. As both KF1 and KF2 were conducted in
each assay, generally it will refer to KF in the following. TA
was purchased from Cayman Chemical Company, USA.
2.2. MTT. NFs and KFs were divided into different groups
for pretreatment with TA (10−3M, 10−4M, 10−5M, or 10−6M)
for different periods (24 h, 48 h, or 72 h), respectively. An
MTT kit (Invitrogen, Life Technologies, USA) was used for
the proliferation assay. Absorbance was detected at 535 nm in
a Packard Fusion spectrophotometer [27]. Relatives of Cell
proliferation rate (%) were determined with cell cultures and
analyzed according to the following equation:
Fibroblast proliferation rate (%)
=
OD535 (TA treatment group)
OD535 (Non-TA treatment group)
.
(1)
All experiments were performed independently. Six times
with keloid fibroblast cultures culture as well as normal skin
dermal culture.
2.3. Apoptosis. NFs and KFs were divided into three groups
Control (“C”, only treated with medium), Vehicle (“V”,
medium 0.55% DMSO), and TA (550 𝜇M TA dissolved in
0.55% DMSO with medium) for 48 h exposure separately.
Annexin-binding buffer (Invitrogen, Life Technologies,USA)
and propidium iodide (Invitrogen, Life Technologies, USA)
working solutions were prepared at 1X. Cell apoptosis were
detected by a fluorescence-activated cell sorting (FACS)
Calibur Flow Cytometer (Accuri C6, Inc., USA) [20, 21].
All experiments were performed independently. Four times
with keloid fibroblast cultures culture as well as normal skin
dermal culture.
2.4. Collagen Staining. NFs and KFs were divided into three
groupsControl (“C”, only treatedwithmedium),Vehicle (“V”,
medium 0.55% DMSO), and TA (550 𝜇M TA dissolved in
0.55% DMSO with medium) for 48 h exposure separately.
Sirius red/Fast green staining kit (Chondrex, USA) was used
to analyze collagen production. Absorbances at 535 nm and
600 nm were detected by a Packard Fusion spectrophotome-
ter and analyzed by the following equation:
Collagen (𝜇g/well) = OD535 − 0.291 ∗OD600
0.037
. (2)
All experiments were performed independently. Four times
with keloid fibroblast cultures culture as well as normal skin
dermal culture.
2.5. Western Blot. NFs and KFs were divided into three
groupsControl (“C”, only treatedwithmedium),Vehicle (“V”,
medium 0.55% DMSO), and TA (550 𝜇M TA dissolved in
0.55% DMSO with medium) for 48 h exposure separately.
Proteins were extracted from each cell line and the concen-
trations were measured by BCA assay. Sixty micrograms of
each sample were mixed with 10 𝜇L of 5X protein sample
loading buffer. The trans-blotted PVDF membrane was then
blocked with blocking buffer (3% BSA; 1X TBS; and 0.05%
Tween-20) for 1 h. Afterward, It was incubated with rabbit
monoclonal anti-human collagen type I (dilution 1 : 2000,
Thermo Fisher Scientific, USA), over two nights at 4∘C.
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Figure 2: The dose- and time-responses of TA on cell proliferation in NFs and KFs. In 48 h exposure time group and 72 h exposure time
group, 10−3M TA significantly decreased cell proliferation in NFs. 0, 10−6, 10−5, 10−4, 10−3, 0.55 × 10−3: M TA was dissolved in 1% DMSO.
∗
𝑃 < 0.01, 10−3M versus 0M; +𝑃 < 0.01, 48 h versus 24 h; #𝑃 < 0.01, 10−3M versus 0M or 10−4M; &𝑃 < 0.01, 72 h versus 24 h or 48 h;
∗∗
𝑃 < 0.01, 10−3M versus 0M; ++𝑃 < 0.05, 48 h versus 24 h; ##𝑃 < 0.05, 10−3M versus 0M; &&𝑃 < 0.01, 72 h versus 24 h or 48 h; 𝑛 = 6.
Anti-rabbit HRP-conjugated secondary antibody (dilution
at 1 : 20000, Sigma, USA) was then added to the membrane
on a shaker for an hour at room temperature. After rinsing
with TBST, the membrane was activated with chemilumi-
nescent HRP substrate (Cell Signaling Technology, USA) for
4min in the dark at room temperature. It was visualized
and quantified using a chemiluminescent detection system
(Bio-Rad, USA). Protein band intensity in each lane was
scored by volume intensity and was normalized to beta-actin
(dilution at 1 : 4000, Sigma, USA) [27]. All experiments were
performed independently. Four times with keloid fibroblast
cultures culture as well as normal skin dermal culture.
2.6. Statistics. Statistical analysis was performed with STA-
TISTICA version 6.0 (StatSoft, Inc. USA). Data are displayed
as mean ± SEM which was evaluated by one-way ANOVA
between two groups in this study. 𝑃 < 0.05 was considered
statistically significant for all tests.
3. Results
3.1. Dose- and Time-Response of TA on NFs and KFs Cell
Proliferation. The effect of TA on NFs and KFs proliferation
was evaluated by MTT analysis and this is displayed in
Figure 2. At the highest concentration of TA, cell proliferation
rates appeared to decrease. As the exposure time increased,
NF and KF proliferation sharply decreased at 10−3MTA. Cell
proliferation also decreased at a greater rate when TA was
applied over 48 or 72 hours. Based on the results of this assay,
0.55 × 10−3M TA at 48 h exposure was determined to be the
ideal condition for future experimentation.
3.2.The Effect Dose and Time of TA on Inducing Cell Apoptosis
in KFs. To determine whether TA induced cell apoptosis on
NFs and KFs, Annexin-V/PI labeling was administered after
applying 0.55 × 10−3M TA dissolved in 0.55% DMSO for
48 h. Although the vehicle alone exhibited an effect on NFs,
selectively significant apoptosis in TA-treated KFs compared
with non-TA treatment groups of KFs and in NFs (Figure 3).
3.3. The Effect Dose and Time of TA on Inhibiting Collagen
Accumulation in KFs. Quantitative analysis of intracellular
and extracellular Sirius red fluorescent staining reflects the
degree of all types of collagen produced by fibroblasts. Results
indicated that collagen production was significantly reduced
in KFs at the previously determined dose and time (Figure 4).
Additionally, there was a considerable morphological change
in KFs. Stained intensity decreased in all samples. Secreted,
stained proteins and cell density were both reduced, espe-
cially in KF cultures.
3.4.TheEffect Dose andTime of TA onReducing the Expression
of Collagen Type I in KFs. The effects of TA on collagen type
I (Collagen I) protein expression were evaluated by Western
blot in both cell types. Protein quantity was measured 48
hours after each treatment. Figure 5 shows a strong increased
expression in KFs compared to NFs. TA significantly sup-
pressed the expression of collagen type I in KFs compared
with the other groups, while the inhibition of collagen type I
expression inNFs after TA treatment was not significant.This
result demonstrated that 0.55 × 10−3M TA for 48 h inhibits
collagen I expression significantly in KFs but not, effectively
in NFs.
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Figure 3: The effect of TA on cell apoptosis in NFs and KFs. DMSO induced early and late apoptosis in NFs and slightly induced early
apoptosis in KFs. TA strikingly induced late apoptosis in KFs. C: control, total medium; V: vehicle, 0.55% DMSO; TA, 0.55 × 10−3M of TA
was dissolved in 0.55% DMSO. ∗𝑃 < 0.01, V versus C or TA; #𝑃 < 0.05, TA versus V; ##𝑃 < 0.05, TA versus C; &&𝑃 < 0.01, TA versus TA;
𝑛 = 6.
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Figure 4:The effect of TA on collagen production in NF and KF after Sirius red staining. DMSO significantly increased collagen production
in NFs. TA strikingly reduced collagen production in KFs compared with NFs. C: control, total medium; V: vehicle, 0.55% DMSO; TA, 0.55 ×
10−3M of TA was dissolved in 0.55% DMSO. ∗𝑃 < 0.01, V versus C; #𝑃 < 0.05, TA versus V; ##𝑃 < 0.05, TA versus C; &&𝑃 < 0.01, TA versus
V; 𝑛 = 4.
4. Discussion
Keloid scaring, a type of scars, is a fibroproliferation dis-
ease with the accumulation of collagen deposition caused
by the upregulation of autocrine TGF-𝛽 signaling during
the wound healing process [5, 13, 27]. The role of TA, a
fenamate and NASID, has been used recently for cancer
treatments [13, 14, 19–25]. These experiments were designed
to determine if the administration of TA is able to alter the
proliferatory rates of keloid fibroblasts and decrease collagen
production in KFs. Our preliminary study demonstrates that
TA has the potential to normalize some of the characteristic
6 Dermatology Research and Practice
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Figure 5: The effect of TA on the expression of collagen type I in NFs and KFs. DMSO slightly increased the expression of collagen type I in
KFs. TA significantly inhibited the expression of collagen type I in KFs. C: control, total medium; V: vehicle, 0.55% DMSO; TA, 0.55 × 10−3M
of TA was dissolved in 0.55% DMSO. +𝑃 < 0.05, C versus C; &𝑃 < 0.05, V versus NFs C; #𝑃 < 0.05, TA versus V; 𝑛 = 4.
features of KFs such as cell apoptosis and collagen produc-
tion.
Initially, we tested the effects of TA on NF and KF
proliferation by applying five concentrations of TA (10−3M,
10−4M, 10−5M, and 10−6M) for 3 different exposure times
(24 h, 48 h, and 72 h) separately in order to determine the con-
ditions at whichminimal drug concentration had the greatest
proportionate effect on disease fibroblasts. We found that NF
and KF proliferation rates were decreased with the 10−3MTA
after 48 h exposure.This indicated that the diversity ofNF and
KF proliferation were significantly reduced by certain higher
amount of TA. Linear extrapolation of cell proliferation assay,
data at 48 h revealed that the effective concentration of TA
which can result in half reduction of NF proliferation was
550𝜇M. This concentration of TA at 48 h exposure did not
show a significant reduction in KFs proliferation, but other
effects were still expected to be present. At 72 hours, there
was a large reduction in proliferation of KF cultures versus
NFs.This may be due to a long-phase response to TA toxicity
in KF or a side effect of changing culture media every three
days. To further qualify the effects of this TA does and
time exposure treatment, we conducted cell apoptosis assays
with 0.55 × 10−3M TA and with 48 h time exposure. A
group exposed to 0.55% DMSO in medium was added to
control for vehicle effects. Though 0.55% DMSO induced a
proportional apoptotic rate in NFs and KFs, cell apoptosis
in KFs after TA treatment induced a selectively significant
apoptotic rate compared to NFs. This indicated that cell
apoptosis was significantly influenced by TA. According
to the typical histological changes in KFs [1–4], reducing
collagen production is a primary pharmacological target to
treat keloid scarring. In our study, we tested the effects of TA
on decreasing the accumulation of collagen and furthermore
tried to verify a relationship between cell apoptosis and
collagen deposition. Based on our data, a high inhibition rate
of collagen productionwas detected inKFs after 0.55× 10−3M
TA with 48 h exposure time compared with NFs. Although
the effect of 0.55% DMSO increased collagen production
in NFs, the production caused by 0.55% DMSO did not
show specific significance in KFs. Concurrently, after TA
treatment, cell number also decreased.Therefore, TA reduced
collagen production in KFs with high efficiency. The Sirius
red collagen quantification assay targets the helical collagen
repeat bundles and is therefore nonspecific for specific types
of collagens. The majority of collagen produced by KFs is
collagen type I, and our results were specific for collagen type
I after TA treatment [1, 2, 12, 26–28]. Our study confirms that
collagen I is overexpressed in KFs versusNFs. Treatment with
TA in vitro significantly decreased collagen expression in KFs
over NFs.
In the cell apoptosis and collagen expression experiments,
DMSO vehicle alone did have some effects compared to con-
trol group.The underlyingmechanism for this is not apparent
from our study. In cell apoptosis assays, compared with
the treatment group, the vehicle group had more significant
effect in NFs while the effect in KFs is not significant. This
may be further considered for clinical studies. In collagen
expression assays, DMSO did not significantly induce colla-
gen expression in NFs. In KFs, it significantly increased the
expression of collagen but this effect can be reversed by TA.
In summary, DMSO did not influence the performance of TA
on cell apoptosis and collagen expression in KFs.The present
study is limited by the number of samples. Nonetheless,
statistically significant effects were seen from TA treatment
in KF cells. A potential mechanism for the activity of TA
in keloid is its capacity to induce degradation of the Sp2
transcription factor. Sp1 has a role in the canonical TGF-𝛽
transduction pathway. Because TGF-𝛽 is widely regarded
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as the central progenitor of fibrotic scars and has a large
capacity for autocrine signaling, the degradation of Sp1 may
serve as a putative pharmacological target in keloids. Future
studies may include the use of TGF-𝛽 receptor blockers
and measuring intracellular phosphorylated SMAD family
members. Other studies may include work to refine the
dosage with respect to solubility without a vehicle. Although
a genetic mouse model does not yet exist for keloids, there
are still valid models of keloid and hypertrophic scarring
that may function to validate the mechanism and activity
of TA in this disease. Despite the shortcomings of this
preliminary study, TA has clear potential to selectively treat
keloid fibroblasts over normal dermal fibroblasts. Numerous
other small-molecule treatments have been tested in keloids,
but TA and fenamates on the whole, have not been explored.
Generally speaking, our current novel data demonstrated
that tolfenamic acid induced cell apoptosis and inhibited
collagen production in keloid fibroblasts. TA could be the
new therapeutical application for treating keloid scars. With
the development of the advanced technologies, hundreds and
thousands of treatments on keloid scar have been reported.
However, this is the first time where TA was successfully
used in vitro to induce cell apoptosis and reduce collagen
accumulation in KFs. Furthermore, TA is an available com-
mercial formulation chemical. Thereby, TA is recommended
for clinical trials to confirm our findings.
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